Paclitaxel and Cisplatin with Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Stage IIIB Non-small Cell Lung Cancer / 대한방사선종양학회지
The Journal of the Korean Society for Therapeutic Radiology and Oncology
; : 223-229, 2006.
Article
Dans Ko
| WPRIM
| ID: wpr-40233
Responsable en Bibliothèque :
WPRO
ABSTRACT
PURPOSE:
Combined modality therapy including chemotherapy, surgery and radiotherapy is considered the standard of care for the treatment of stage III non-small cell lung cancer (NSCLC). This study was conducted to evaluate the efficacy of paclitaxel and cisplatin with induction chemotherapy followed by concurrent chemoradiotherapy for stage IIIB NSCLC. MATERIALS ANDMETHODS:
Between July 2000 and October 2005, thirty-nine patients with stage IIIB NSCLC were treated with two cycles of induction chemotherapy followed by concurrent chemoradiotherapy. The induction chemotherapy included the administration of paclitaxel (175 mg/m2) by intravenous infusion on day 1 and treatment with cisplatin (75 mg/m2) by intravenous infusion on day 1 every 3 weeks. Concurrent chemoradiotherapy included the use of paclitaxel (60 mg/m2) plus cisplatin (25 mg/m2) given intravenously for 6 weeks on day 43, 50, 57, 71, 78 and 85. Thoracic radiotherapy was delivered with 1.8 Gy daily fractions to a total dose of 54~59.4 Gy in 6~7 weeks (median 59.4 Gy).RESULTS:
The follow up period was 6~63 months (median 21 months). After the induction of chemotherapy, 41.0% (16 patients) showed a partial response and 59.0% (23 patients) had stable disease. After concurrent chemoradiotherapy, 10.3% (4 patients) had a complete response, 41.0% (16 patients) had a partial response, and the overall response rate was 51.3% (20 patients). The 1-, 2-, 3-year overall survival rates were 66.7%, 40.6%, and 27.4% respectively, with a median survival time of 20 months. The 1-, 2-, 3-year progression free survival rates were 43.6%, 24.6%, and 24.6%, respectively, with median progression free survival time of 10.7 months. Induction chemotherapy was well tolerated. Among 39 patients who completed the entire treatment including chemoradiotherapy, 46.3% (18 patients) had esophagitis greater than grade 3 and 28.2% (11 patients) had radiation pneumonitis greater than grade 3.CONCLUSION:
Paclitaxel and cisplatin with induction chemotherapy followed by concurrent chemoradiotherapy for stage IIIB NSCLC seems to be an effective treatment. Occurrence of esophagitis and pneumonitis represents a significant morbidity and suggests a modification of the treatment regimen, either with the chemotherapy schedule or with radiotherapy treatment planning.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Rendez-vous et plannings
/
Pneumopathie infectieuse
/
Radiothérapie
/
Perfusions veineuses
/
Taux de survie
/
Études de suivi
/
Cisplatine
/
Paclitaxel
/
Poumon radique
/
Association thérapeutique
Type d'étude:
Observational_studies
/
Prognostic_studies
Limites du sujet:
Humans
langue:
Ko
Texte intégral:
The Journal of the Korean Society for Therapeutic Radiology and Oncology
Année:
2006
Type:
Article